CytomX Therapeutics, Inc.
Symbol: CTMX (NASDAQ)
Company Description:
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
- Today's Open: $2.09
- Today's High: $2.16
- Today's Low: $2.055
- Today's Volume: 639.04K
- Yesterday Close: $2.07
- Yesterday High: $2.135
- Yesterday Low: $2.06
- Yesterday Volume: 1.57M
- Last Min Volume: 400
- Last Min High: $2.055
- Last Min Low: $2.055
- Last Min VWAP: $2.055
- Name: CytomX Therapeutics, Inc.
- Website: https://www.cytomx.com
- Listed Date: 2015-10-08
- Location: SOUTH SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001501989
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $341.37M
- Round Lot: 100
- Outstanding Shares: 164.91M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-08-21 | SCHEDULE 13G | View |
2025-08-18 | EFFECT | View |
2025-08-14 | SCHEDULE 13G | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-13 | 8-K | View |
2025-08-07 | S-8 | View |
2025-08-07 | S-3 | View |
2025-08-07 | 8-K | View |
2025-08-07 | 10-Q | View |
2025-08-06 | SCHEDULE 13G | View |
2025-07-29 | SCHEDULE 13G/A | View |
2025-07-09 | SCHEDULE 13G/A | View |
2025-07-09 | SCHEDULE 13G/A | View |
2025-06-17 | 4 | View |
2025-06-17 | 4 | View |
2025-06-17 | 4 | View |
2025-06-13 | 4 | View |
2025-06-13 | 4 | View |
2025-06-13 | 4 | View |